Quick Answer
Gain Therapeutics, Inc. reported Long-Term Debt of $300.1 thousand for fiscal year 2025.
Gain Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $300.1K | -8.6% |
| 2024 | $328.3K | -26.9% |
| 2023 | $449.1K | -9.3% |
| 2022 | $495.3K | -16.1% |
| 2021 | $590.5K | -17.5% |
| 2020 | $715.7K | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $298.8K | -20.6% | -8.2% |
| June 30, 2025 | $325.4K | -13.3% | +3.5% |
| March 31, 2025 | $314.5K | -20.8% | -4.2% |
| December 31, 2024 | $328.3K | -26.9% | -12.7% |
| September 30, 2024 | $376.1K | -13.5% | +0.2% |
| June 30, 2024 | $375.4K | -19.6% | -5.4% |
| March 31, 2024 | $396.8K | -17.0% | -11.6% |
| December 31, 2023 | $449.1K | -9.3% | +3.2% |
- Gain Therapeutics, Inc. showed a decrease of -8.6% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2025 period, Gain Therapeutics, Inc.’s long-term debt has declined by 58.1% (from $715.7 thousand to $300.1 thousand).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: